HeartMate III is a next-generation continuous flow left ventricular assist device (:LVAD) based on fully magnetically levitated technology. This technology helps in reducing adverse event rates ...

Thoratec Corp. THOR recently announced that it has received the final approval from the FDA to broaden enrollment of its HeartMate III U.S. IDE clinical trial, which commenced in September last year.

Manufacturer and marketer of medical devices used for mechanical circulatory support, Thoratec Corp.THOR, recently announced that the first HeartMate III implant has been conducted via ...

Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, today announced that it received final ...

PLEASANTON, Calif., June 27, 2014 /PRNewswire/ --Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing ...

FDA has granted Thoratec Corp. permission to enlarge its pivotal trial for the next-generation HeartMate III left ventricular assist system (LVAS). This gives the company the ability to enroll a ...

Please provide your email address to receive an email when new articles are posted on . Thoratec Corporation announced that it has received approval from the FDA to expand enrollment of the HeartMate ...

Thoratec shed almost one-third of its value after reporting abysmal second quarter earnings. The advanced heart failure device company attributed most of the miss to a New England Journal of Medicine ...

A surgical team in Toronto has successfully implanted a novel mechanical device, the HeartMate IIITM, into a patient with advanced heart failure. This is the first time this procedure has been ...

Abbott has issued a recall for select HeartMate mobile power units used with its HeartMate3 and HeartMate III left-ventricular assist systems due to risk of sudden power loss that could lead to ...

Thoratec Corp ( THOR) recently completed enrollment of 50 patients under the HeartMate III CE Mark trial at ten sites across Europe, Canada and Australia. The trial will monitor these patients over ...

Upbeat phase III findings outweighed less encouraging late-stage trial news, as big pharma provided a mixed bag of cancer findings – with one data batch to form... By creating a new mouse model of ...